In this update, I'll focus on Organon's Q3 2024 results, earnings adjustments and segment performance, as well as the ...

Organon is a strong investment opportunity with a high yield, diversified portfolio, steady performance, and transformative ...

Organon said that as a result of the delay, it now expects Vtama to contribute about $125 million in revenue next year, with the Dermavant deal reducing its 2025 adjusted earnings before interest ...

statements about management’s expectations regarding Organon’s recent acquisition of Dermavant Sciences Ltd. (“Dermavant”) and potential regulatory approval from the FDA for the use of ...

As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...

Appleby Bermuda advised Organon & Co on the acquisition, by way of merger under Bermuda law, of Dermavant Sciences Ltd. Organon (NYSE: OGN) is a global healthcare company with a mission to improve the ...

Organon is paying $175 million upfront to buy Roivant's dermatology unit Dermavant and its topical psoriasis therapy Vtama, which is also under review by the FDA for atopic dermatitis. The AI ...

Avid Bioservices has agreed a deal to be acquired by private equity firms GHO Capital Partners and Ampersand Capital Part Organon is paying $175 million upfront to buy Roivant's dermatology unit ...

Leerink Partners analyst David Risinger has reiterated their bullish stance on ROIV stock, giving a Buy rating yesterday. David Risinger has ...

Organon & Co. (NYSE:OGN) shareholders are probably feeling a little disappointed, since its shares fell 3.1% to US$16.92 in the week after its latest quarterly results. Results were roughly in ...